DDInter458 DDInter860
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Hepatitis B Vaccine is an ingredient in the EMA-withdrawn product Quintanrix. It is marketed in Canada as Engerix B. It is also a part of Twinrix (Hep A/Hep B vaccine) available also in Canada. The hepatitis B virus induces a severe form of viral hepatitis. Other causative agents are hepatitis A virus, and the non-A, non-B hepatitis viruses. Hepatitis D virus, a defective virus requiring the “keeper function” of the hepatitis B virus, occurs either as a co-infection or super-infection in a HBsAg carrier. Transmission of the virus occurs through percutaneous contact with contaminated blood, serum or plasma. Infection may also occur by the exposure of mucous surfaces, or intact or damaged skin to other body fluids such as saliva, mucosal secretions and semen. There is no specific treatment for hepatitis. The incubation period may be as long as 6 months, followed by a very complex clinical course of an acute or chronic nature, often leading to hospitalization. Viral hepatitis caused by hepatitis B virus is a major worldwide health problem, though the incidence and epidemiology vary widely among geographical areas and population subgroups. In Canada, the United States and Northern Europe, 4% to 6% of the population are infected during their lifetime (mostly young adults); between 5% and 10% of infections lead to persistent viremia (carrier state). Certain population subgroups in these areas, however, are at high risk (see Indications and Clinical Use). In Asia, infection often occurs early in life, leading to a hepatitis B marker prevalence of more than 70% in the general population and a carrier rate of up to 20%. It is estimated that the reservoir of persistent hepatitis B surface antigen carriers amounts to 350 million people worldwide. Carriers are at a high risk of developing chronic liver disease which may lead to cirrhosis or primary hepatocellular carcinoma. A significant reduction in the incidence of hepatocellular carcinoma has been observed in children aged 6 to14 years following a nationwide hepatitis B vaccination in Taiwan. This resulted from a significant decline in the prevalence of hepatitis B antigen, the persistence of which is an essential factor in the development of hepatocellular carcinoma. Vaccination against hepatitis B is expected in the long term to reduce the overall incidence of both hepatitis B and the chronic complications such as chronic active hepatitis and cirrhosis.
Cyclosporine {u} (Compound) binds {v} (Gene) SLC22A6
SLC22A6 {u} (Gene) is bound by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) downregulates {v} (Gene) TYMS
TYMS {u} (Gene) is bound by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) upregulates {v} (Gene) INPP1
INPP1 {u} (Gene) is upregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) downregulates {v} (Gene) TK1
TK1 {u} (Gene) is downregulated by {v} (Compound) Azacitidine
Azacitidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) downregulates {v} (Gene) CCND3
CCND3 {u} (Gene) is upregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) upregulates {v} (Gene) LIPA
LIPA {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) downregulates {v} (Gene) AURKA
AURKA {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is downregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) binds {v} (Gene) ABCC10
ABCC10 {u} (Gene) is upregulated by {v} (Compound) Topotecan
Topotecan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine {u} (Compound) downregulates {v} (Gene) PSMD2
PSMD2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) downregulates TYMS (Gene) and TYMS (Gene) is bound by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) upregulates INPP1 (Gene) and INPP1 (Gene) is upregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) downregulates TK1 (Gene) and TK1 (Gene) is downregulated by Azacitidine (Compound) and Azacitidine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) downregulates CCND3 (Gene) and CCND3 (Gene) is upregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) upregulates LIPA (Gene) and LIPA (Gene) is downregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) downregulates AURKA (Gene) and AURKA (Gene) is bound by Epirubicin (Compound) and AURKA (Gene) is downregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) binds ABCC10 (Gene) and ABCC10 (Gene) is upregulated by Topotecan (Compound) and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)
Cyclosporine (Compound) downregulates PSMD2 (Gene) and PSMD2 (Gene) is bound by Bortezomib (Compound) and PSMD2 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis B Vaccine (Recombinant)